Pas de connexion internet — affichage de la version enregistrée de la page.

Regeneron Pharmac…

USUSD
← Vers le screener
US:REGNLSE:0R2M

Regeneron Pharmaceuticals Inc (US:REGN) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site web
regeneron.com
Secteur
Health Care · Biotechnology: Pharmaceutical Preparations
Siège social
Eastview, United States
PDG
Dr. Leonard S. Schleifer M.D., Ph.D.
Employés
15 410
Fondée
1988
Actions en circulation
101.14 M
Flottant
95.85 M
Capitalisation boursière
75.65 Md USD
Initiés
2.09%
Investisseurs institutionnels
93.55%
Secteur d'activité (SIC)
Pharmaceutical Preparations
ISIN
US75886F1075
LEI
549300RCBFWIRX3HYQ56
Taux de distribution
8.7%
FCF
3.58 Md USD
11%
Dette
2.71 Md USD
0.8 ans de FCF
Ancienneté du dividende
1 ans
Bénéfices, FCF et dividendes versés — pour les 12 mois précédant 30.06.2026 (le dernier rapport de l'entreprise).
Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Bourses et tickers

BourseTickerDevisePrixType
US USA StocksREGN principaleUSD739.57 -0.34%actions ordinaires
LSE London Stock Exchange0R2M IOBUSD730.04 -0.27%actions ordinaires

Cours sur 3 mois

jour de hausse jour de baisse date de détachement du dividende date de versementSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Dividendes

12 derniers mois, US:REGN: 3.7 USD (4 vers.)

Regeneron Pharmaceuticals Inc (REGN) verse des dividendes trimestriels. Au cours des 12 derniers mois, 3.7 USD par action ont été versés (versements : 4). Cela représente environ 0.50% du cours actuel de l'action. D'après l'historique des paiements, la prochaine date ex-dividende est prévue vers 17.11.2026.

Date exVersementMontant%TypeTicker
2026-08-182026-08-310.9400 USD0.1/0.5 %trimestrielUS:REGN
2026-05-202026-06-040.9400 USD0.1/0.5 %trimestrielUS:REGN
2026-02-202026-03-050.9400 USD0.1/0.5 %trimestrielUS:REGN
2025-11-202025-12-050.8800 USD0.1/≈0.5 %trimestrielUS:REGN
2025-08-182025-09-030.8800 USD0.1/≈0.5 %trimestrielUS:REGN
2025-05-202025-06-060.8800 USD0.1/≈0.5 %trimestrielUS:REGN

Actualités de cette semaine

Pas encore d'actualités du site de l'entreprise.

publicité

Principaux actionnaires

DétenteurParticipationActionsDate du rapport
Blackrock Inc.9.01%9.11 M2026-06-30
Vanguard Capital Managem…6.56%6.63 M2026-06-30
Dodge & Cox Inc.4.82%4.87 M2026-06-30
State Street Corporation4.78%4.83 M2026-06-30
Invesco Ltd.3.9%3.94 M2026-06-30
JPMORGAN CHASE & CO3.73%3.77 M2026-06-30
VANGUARD INDEX FUNDS-Van…3.23%3.27 M2026-06-30
Vanguard Portfolio Manag…3.14%3.18 M2026-06-30
Dodge & Cox Funds-Dodge…3.09%3.12 M2026-06-30
Franklin Resources, Inc.2.74%2.77 M2026-06-30
Geode Capital Management…2.6%2.63 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.56%2.59 M2026-06-30
Invesco QQQ Trust, Serie…2.19%2.22 M2026-08-31
Nuveen, LLC2%2.02 M2026-06-30
iShares Trust-iShares Co…1.32%1.33 M2026-08-31
Fidelity Concord Street…1.28%1.29 M2026-07-31
SPDR S&P 500 ETF TRUST-S…1.21%1.22 M2026-08-31
PUTNAM LARGE CAP VALUE F…1.14%1.15 M2026-07-31
YANCOPOULOS GEORGE D (Pr…≈1.11%1.13 M2025-12-31
VANGUARD INDEX FUNDS-Van…1.1%1.12 M2026-06-30
VANGUARD SPECIALIZED FUN…1.06%1.07 M2026-07-31
SCHLEIFER LEONARD S (Chi…≈0.68%687 9812025-12-31
MURPHY ANDREW J (Officer…≈0.06%56 4372025-12-05
LAROSA JOSEPH J (General…≈0.05%45 5952026-08-19
VAN PLEW DANIEL P (Offic…≈0.04%37 7302025-12-05
SING GEORGE LOUIS (Direc…≈0.03%33 1572026-01-02
FENIMORE CHRISTOPHER R (…≈0.02%23 5052026-08-18
RYAN ARTHUR F. (Director…≈0.02%17 3032026-07-02
MCCOURT MARION E (Office…≈0.02%15 5672025-12-05
BROWN MICHAEL S (Directo…≈0.01%12 8652026-01-02